Next 10 |
home / stock / casbf / casbf news
2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...
2023-08-08 13:19:10 ET More on AstraZeneca AstraZeneca: Robust Performance And Promising Growth Initiatives AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade) AstraZeneca: Solid Earnings Report Reinforces Medium To Long-Term Upside ...
2023-05-18 14:13:29 ET Following a meeting of an advisory panel, the World Health Organization announced its recommendations supporting the use of reformulated COVID vaccines to reflect the currently dominant variants such as XBB.1 Noting that XBB.1 descendent lineages have outnumbered ...
2023-05-09 11:29:00 ET Summary Fosun Pharma’s revenue grew slightly in the first quarter on its diverse product portfolio, while its net profit soared by 116%. CanSino’s revenue plunged 80% in the same three-month period, and it swung to the red on heavy marketing an...
2023-05-04 14:28:34 ET A panel of experts at the World Health Organization (WHO) is expected to meet on Thursday to discuss whether the current COVID-19 pandemic will remain a global emergency, the U.N. agency's highest alert level. The head of the WHO, Dr. Tedros Adhanom Ghebreyesus, i...
2023-04-06 14:14:11 ET After more than three years, the World Health Organization (WHO) could announce an end to the emergency status of COVID-19 this year, the head of the global body Dr. Tedros Adhanom Ghebreyesus, said Thursday. In early 2020, the WHO named the COVID-19 pandemic a Pu...
2023-03-28 12:05:00 ET The World Health Organization (WHO) issued revised recommendations for prioritizing the use of COVID-19 vaccines on Tuesday, including healthy children and adolescents in a low-priority group for immunizations. The announcement follows a meeting of the agency&...
2023-03-07 09:08:00 ET Summary The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades. CanSino logged sizable asset impairments for its unsold Covid vaccines last year, pointing to the challenge of oversupply. The comp...
Summary After successful listings in Shanghai and Hong Kong, vaccine maker CanSino is preparing to move into Europe with a listing in Switzerland. Sales could surge for the company’s Covid-19 vaccines as China launches a nationwide campaign for a new round of boosters. Despit...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CanSino Biologics (OTCMKTS: CASBF ) are ripping higher on Wednesday, with CASBF stock up about 75% on the day. The move is startling, particularly given the poor price action we were seeing in the overall stock market...